You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Imatinib-refractory/resistant

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Gastrointestinal Stromal Tumors Trial in Worldwide (RAD001, Imatinib 600mg/day (Glevec is the brand name for imatinib), Imatinib

Completed
Has Results
  • Gastrointestinal Stromal Tumors
  • Boston, Massachusetts
  • +15 more
Jun 3, 2021

Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia Trial in Aichi (Nilotinib)

Completed
  • Chronic Myelogenous Leukemia
  • Acute Lymphoblastic Leukemia
  • Aichi, Japan
    Novartis Investigative Site
Dec 6, 2020

Gastrointestinal Stromal Tumors (GISTs) Trial in Seoul (Imatinib Mesylate)

Completed
  • Gastrointestinal Stromal Tumors (GISTs)
  • Imatinib Mesylate
  • Seoul, Korea, Republic of
    Asan Medical Center
Dec 30, 2022

Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive) Trial in Tokyo (Nilotinib)

Completed
  • Chronic Myelogenous Leukemia
  • Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
  • Tokyo, Japan
    Novartis Investigative Site
Dec 6, 2020

Advanced, Refractory Cancer Trial in Seoul (Imatinib)

Active, not recruiting
  • Advanced, Refractory Cancer
  • Seoul, Korea, Republic of
    Samsung Medical Center
Jun 13, 2022

Eosinophilic Myeloid Tumor, Hypereosinophilic Syndrome Trial run by the National Institute of Allergy and Infectious Diseases

Recruiting
  • Eosinophilic Myeloid Neoplasm
  • Hypereosinophilic Syndrome
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 25, 2023

Epilepsy Trial in Beijing (PINS Vagus Nerve Stimulator)

Recruiting
  • Epilepsy
  • PINS Vagus Nerve Stimulator
  • Beijing, Beijing, China
    Peking University First Hospital
Aug 7, 2023

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic

Recruiting
  • Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +2 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 15, 2022

ALK+ Anaplastic Large Cell Lymphoma Trial in Wien (Brentuximab vedotin, Imatinib)

Terminated
  • ALK+ Anaplastic Large Cell Lymphoma
  • Wien, Austria
    Universitätsklinik f. Innere Medizin I, AKH Wien, Klinische Abte
Feb 15, 2022

Metastatic Castration Resistant Prostate Cancer Trial in United States (LAVA-1207)

Recruiting
  • Metastatic Castration Resistant Prostate Cancer
  • LAVA-1207
  • Tampa, Florida
  • +3 more
Nov 18, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Completed
Has Results
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +8 more
  • Bevacizumab
  • Irinotecan Sucrosofate
  • Chicago, Illinois
    Northwestern University
Dec 21, 2022

Malignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma Trial in

Recruiting
  • Malignant Ovarian Epithelial Tumor
  • +9 more
  • Akt/ERK Inhibitor ONC201
  • +2 more
  • Detroit, Michigan
    Barbara Ann Karmanos Cancer Institute
May 10, 2022

Prostate Cancer, Refractory Cancer, Castration Resistant Prostatic Cancer Trial in Winston-Salem (Omeprazole 80 mg twice daily)

Recruiting
  • Prostate Cancer
  • +2 more
  • Omeprazole 80 mg twice daily
  • Winston-Salem, North Carolina
    Wake Forest Baptist Comprehensive Cancer Center
Jan 5, 2023

Refractory Epilepsy, Epilepsy Trial in Winston-Salem (Exercise program, Health Coach, Health Information)

Terminated
  • Refractory Epilepsy
  • Epilepsy
  • Exercise program
  • +2 more
  • Winston-Salem, North Carolina
    Wake Forest University Health Sciences
Dec 4, 2022

Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer Trial in Orlando, Albuquerque

Recruiting
  • Platinum-resistant Ovarian Cancer
  • +6 more
  • olvimulogene nanivacirepvec
  • +3 more
  • Orlando, Florida
    AdventHealth Cancer Institute
Sep 1, 2022

Hormone-refractory Prostate Cancer Trial (AMX-500)

Not yet recruiting
  • Hormone-refractory Prostate Cancer
  • (no location specified)
Aug 11, 2023

Schizophrenia Trial in Shanghai (sodium valproate with Clozapine, modified electroconvulsive therapy(MECT) with Clozapine,

Completed
  • Schizophrenia
  • sodium valproate with Clozapine
  • +3 more
  • Shanghai, Shanghai, China
    Shanghai Mental Health Center
Sep 1, 2022

Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer Trial in Rochester, Helsinki (TILT-123, Pembrolizumab)

Recruiting
  • Platinum-refractory Ovarian Carcinoma
  • Platinum-resistant Ovarian Cancer
  • TILT-123
  • Pembrolizumab
  • Rochester, Minnesota
  • +1 more
Aug 12, 2022

Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated

Completed
  • Chronic Myeloid Leukaemia
  • Rionero in Vulture, Potenza, Italy
  • +32 more
Oct 24, 2022

Ovarian Cancer, Relapsed or Refractory, Chiauranib Trial in Shanghai (chiauranib, Placebo, Paclitaxel)

Recruiting
  • Ovarian Cancer
  • +3 more
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 7, 2022

Osteosarcoma Trial in China, Korea, Republic of (Sulfatinib, Etoposide, Isophosphamide)

Not yet recruiting
  • Osteosarcoma
  • Beijing, Beijing, China
  • +4 more
Oct 19, 2022

Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Tumors, Prostate Cancer Recurrent Trial (lorigerlimab,

Not yet recruiting
  • Androgen-Independent Prostatic Cancer
  • +8 more
  • lorigerlimab
  • +2 more
  • (no location specified)
May 4, 2023

Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia Trial in Worldwide (Nilotinib)

Completed
Has Results
  • Chronic Myeloid Leukemia
  • Acute Lymphoblastic Leukemia
  • Bordeaux, Aquitaine, France
  • +11 more
Dec 6, 2020

Transcranial Magnetic Stimulation, Drug Resistant Epilepsy, Cerebellum Trial (transcranial magnetic stimulation)

Not yet recruiting
  • Transcranial Magnetic Stimulation
  • +2 more
  • transcranial magnetic stimulation
  • (no location specified)
Mar 29, 2023

Treatment-resistant Depression, MDD Trial in Taipei (Prolonged intermittent theta burst stimulation (piTBS), 20Hz rTMS, sham

Recruiting
  • Treatment-resistant Depression
  • Major Depressive Disorder
  • Prolonged intermittent theta burst stimulation (piTBS)
  • +2 more
  • Taipei, Taiwan
    Taipei Veterans General Hospital, Taiwan
Aug 15, 2022